The Speak Foundation

News

• 2019 MDA Engage DMD Symposium Scheduled on Nov. 9 October 11, 2019
  At MDA, we believe in the power of research and the importance of building relationships among families, clinicians, and the scientists making discoveries to advance treatments and therapies. We invite individuals living with Duchenne muscular dystrophy (DMD), as well as their caregivers and loved ones, to attend the MDA Engage DMD Symposium taking place Nov. […]
• 2019 MDA Engage Charcot-Marie-Tooth Symposium Scheduled on Nov. 9 October 10, 2019
  At MDA, we believe in the power of research and the importance of building relationships among families, clinicians, and the scientists making discoveries to advance treatments and therapies. We invite individuals living with Charcot-Marie-Tooth disease (CMT), as well as caregivers and loved ones, to attend the MDA Engage CMT Symposium taking place Nov. 9 in […]
• 2019 MDA Engage Myotonic Dystrophy Symposium Scheduled in Rochester, NY, on Nov. 9 October 9, 2019
  At MDA, we believe in the power of research and the importance of building relationships among families, clinicians, and the scientists making discoveries to advance treatments and therapies. We invite individuals living with myotonic dystrophy (DM), as well as caregivers and loved ones, to attend the MDA Engage Myotonic Dystrophy Symposium taking place Nov. 9 […]
• Join Us for a Virtual MDA Engage BMD Symposium on Oct. 26 October 8, 2019
  We invite you to attend an upcoming virtual MDA Engage Becker Muscular Dystrophy Symposium where we will share information from experts in the field about Becker muscular dystrophy (BMD).  The online event will take place Oct. 26 from noon-4 p.m. ET. Event chair Dr. Paula Clemens from the University of Pittsburgh School of Medicine and […]
• NS Pharma Submits New Drug Application to FDA for Viltolarsen to Treat DMD Amenable to Exon 53 Skipping October 7, 2019
  On Oct. 2, NS Pharma Inc. (a wholly-owned US subsidiary of Nippon Shinyaku Co. Ltd.) submitted a rolling New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its exon-skipping therapy under development, viltolarsen (previously NS-065/NCNP-01), to treat Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping. On Sept. 26, Nippon Shinyaku […]